What is the main business of Polska Grupa Farmaceutyczna?

The main business activity of Polska Grupa Farmaceutyczna focuses on wholesale of pharmaceutical goods.

When was the company founded?

The company was registered in the Polish National Court Register (KRS) on August 1, 2013.

Where is the headquarters located?

The headquarters is located at: Zbąszyńska 3, 91-342 Łódź.

What is the share capital?

The share capital of the company is PLN 290,000,000 (approx. $78.3 million).

What period do the latest financial data cover?

The latest available financial statement covers the period from January 1, 2025 to December 31, 2025.

What was the revenue?

In 2025, the company generated total revenue of USD 1,632,706,178, representing a decrease of 1.6% compared to 2024.

No, in 2025 the company was not profitable, reporting a net loss of USD 4,722,501. For comparison, in 2024 the loss was USD 1,528,690, meaning the company increased its loss by 208.2%.

Which cost dominates operating expenses?

The largest operating cost category falls under cost of goods and materials sold. This category amounted to USD 1,515,723,506 in 2025, representing 93% of all operating expenses.

Polska Grupa FarmaceutycznaS.A.

Wholesale of pharmaceutical goods

KRS: NIP: REGON:

Overview

Status

Active

Registry date

2013-08-01

Share capital

290 000 000,00 PLN

Activity description

Polska Grupa Farmaceutyczna S.A. is a leading pharmaceutical distributor in Poland. It delivers medicines and medical products to pharmacies, patients, and local communities, working with more than 450 manufacturers. The company operates 13 regional warehouses and delivers 320 million products to pharmacies each year.

Registered address

Zbąszyńska 3, 91-342 Łódź, Poland

Website

pgf.com.pl

Phone

Social media

Electronic delivery address

AE:PL-31091-21482-FRBAF-11

Financials

Total Operating Costs

1.63bn

-0.9% vs 2024

Revenue history (in m)

Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.

Statistics

How the company ranks by revenue within its industry, region and across Poland in 2025.

Results vs industry

Revenue

This companyUSD 1.78bnMedianUSD 874.80kAverageUSD 20.30m

Net profit

This companyUSD -9.53mMedianUSD 28.22kAverageUSD 816.54k

Operating costs

This companyUSD 1.77bnMedianUSD 805.63kAverageUSD 19.09m

Assets

This companyUSD 583.58mMedianUSD 541.73kAverageUSD 10.95m

News

2026-09-21

Statement of the Polish Pharmaceutical Group regarding the decision of the President of UOKiK dated September 21, 2026

2026-09-02

Pharmabus in Your City!

2026-08-26

"By Your Side" – Your Trainer in the Pharmacy

2026-08-25

KSeF Connects Us

2026-02-06

"By Your Side". PGF Supports Pharmacies Business-wise

2026-02-06

PGF Awarded Friendly Workplace 2025 Title

Industry

Bank accounts

Registered as a VAT taxpayer on 2010-12-23. Active

Erste Bank Polska
49 1090 0004 0000 0011 7970 0011
Bank Millennium
21 1160 2202 0000 0004 8779 3541
VeloBank
03 1560 0013 2023 1937 2000 0001

Debt

No entries in the National Debtors Register (KRZ). No proceedings in KRZ

MSiG notices

Publication date	Event
Feb 15, 2021	Lost documents
Oct 13, 2017	Merger registered
Aug 22, 2013	Transformation registered

Public aid

35 public aid cases recorded, with a total value of $246,936.

Grant date	Purpose	Gross amount	Granting body
Jul 10, 2026	De minimis aid (in accordance with Commission Regulation 2023/2831)	$1,690$1,690	Starosta Powiatu Olsztyn
Jun 10, 2026	De minimis aid (in accordance with Commission Regulation 2023/2831)	$7,910$7,910	PREZYDENT MIASTA GDAŃSK
Dec 17, 2025	De minimis aid (in accordance with Commission Regulation 2023/2831)	$4,400$4,400	Prezydent Miasta Stołecznego Warszawy

Tenders

3 tenders recorded as contractor: 1 national ($59,916) and 2 EU ($743,357).

Publication date	Subject	Amount	Contracting authority
Apr 22, 2025	Zakup i dostawa produktów farmaceutycznych IV	$638.5K$638,527	Szpital Miejski Specjalistyczny Im. Gabriela Narutowicza w Krakowie
Apr 22, 2025	Zakup i dostawa produktów farmaceutycznych IV	$104.8K$104,830	Szpital Miejski Specjalistyczny Im. Gabriela Narutowicza w Krakowie
Jun 8, 2022	Dostawy radiofarmaceutyków i odczynników do ZMN	$59,916$59,916	5 Wojskowy Szpital Kliniczny z Polikliniką Sp Zoz w Krakowie

Public sector contracts

Polska Grupa Farmaceutyczna is the contractor in 262 public sector contracts, worth PLN 236.35k in total. They were signed with 29 public buyers. The largest number (192) were signed with Samodzielny Publiczny Zakład Opieki Zdrowotnej Ministerstwa Spraw Wewnętrznych I Administracji w Koszalinie.

Signed	Subject	Public buyer	Value
Oct 14, 2026	Zakup odczynników chemicznych.	Uniwersytet Jagielloński Collegium Medicum	PLN 673.36
Oct 9, 2026	1.Adenocor, 3 mg/ml; 2 ml, roztw.do wstrz., 6 fiol 1 op Adrenalina WZF 0.1%, 1 mg/ml; 1 ml, roztw.do wstrz.,10 amp 1 op Benodil, 0,5 mg/ml; 2 ml, zaw.do nebul., 20 amp 1 op Captopril Jelfa, 12,5 mg, tabl., 30 szt 1 op Clemastinum WZF, 1 mg/ml; 2 ml, roztw.do wstrz., 5 amp 1 op Clopidogrel Krka, 75 mg, tabl.powl., 28 szt 1 op Corhydron 100, 100 mg,prosz,rozp.d/sp.r.d/wst,inf,5fiol+5rozp 1 op Dexaven, 4 mg/ml; 2 ml, roztw.do wstrz.,10 amp 1 op Fentanyl WZF, 50 mcg/ml; 2 ml, roztw.do wstrz., 50 amp 1 op GlucaGen 1mg HypoKit,prosz,rozp.d/sp.r.d/wst,1fiol.pr.+1a-st 2 op Glucosum,20%, 10 ml, inj., 10 amp 1 op Heparinum WZF, 5000 IU/ml; 5 ml, roztw.do wstrz.,10 fiol 1 op Hydroxyzinum Teva, 50 mg/ml; 2ml,rozt.d/wstrzyk.,5amp 1 op Hydroxyzinum VP, 10 mg, tabl.powl., 30 szt,bl(1x30) 1 op Ibuprofen Hasco, 200 mg, kaps.miękkie, 60 szt 1 op Ketonal, 50 mg/ml; 2 ml, roztw.do wstrz., 10 amp 1 op Magnesii sulf. 20% Polpharma, 2 g/10ml, inj.,10 amp 1 op Metoclopramidum 0.5% Polpharma, 5mg/ml; 2ml,roztw.d/wst,5amp 1 op Midanium, 1 mg/ml; 5 ml, roztw.do wstrz.,10 amp 1 op Naloxonum h/chlor.WZF, 400 mcg/ml; 1 ml,roztw.d/wstrz,10 amp 1 op Natr. chloratum,0,9%,inj,KabiClear,20x500ml FrKP Kutno 1 op Nebbud, (0,25 mg/ml); 2 ml, zaw.do nebul.,20 amp 1 op Nitromint, 0,4 mg/dawkę, aer, 11 g (200 dawek) poj.metal. 1 op No-Spa, 20 mg/ml; 2ml,roztw.do wstrz., 5 amp 1 op Optilyte, roztw.do infuz., 500 ml x 20, KabiClear 1 op Papaverinum h/chlor. WZF,20 mg/ml; 2ml, roztw.d/wstrz,10amp 1 op Paracetamol Au	Komenda Miejska Państwowej Straży Pożarnej w Krakowie	PLN 3,758
Oct 9, 2026	Leki	Komenda Miejska Państwowej Straży Pożarnej M.St. Warszawy	PLN 5,874
Oct 8, 2026	zakup i dostawa leków (inactive)	Samodzielny Publiczny Zakład Opieki Zdrowotnej Ministerstwa Spraw Wewnętrznych I Administracji w Koszalinie	PLN 2,255
Oct 8, 2026	zakup i dostawa leków (inactive)	Samodzielny Publiczny Zakład Opieki Zdrowotnej Ministerstwa Spraw Wewnętrznych I Administracji w Koszalinie	PLN 119.06

Public buyer	Value
Uniwersytet Jagielloński Collegium Medicum	PLN 673.36
Komenda Miejska Państwowej Straży Pożarnej w Krakowie	PLN 3,758
Komenda Miejska Państwowej Straży Pożarnej M.St. Warszawy	PLN 5,874
Samodzielny Publiczny Zakład Opieki Zdrowotnej Ministerstwa Spraw Wewnętrznych I Administracji w Koszalinie	PLN 2,255
Samodzielny Publiczny Zakład Opieki Zdrowotnej Ministerstwa Spraw Wewnętrznych I Administracji w Koszalinie	PLN 119.06

Public procurement disputes (KIO)

Polska Grupa Farmaceutyczna has been a party to 8 cases before the National Appeal Chamber (since 2008). It filed 7 appeals (3 upheld, 2 dismissed, 1 discontinued). In 1 case it joined the proceedings as a participant.

Date	Case no.	Role	Other party	Outcome
Apr 16, 2024	KIO 1087/24	Appellant	Wojskowy Ośrodek Farmacji i Techniki Medycznej w Celestynowie	Upheld
Apr 4, 2024	KIO 975/24	Appellant	Wojskowy Ośrodek Farmacji i Techniki Medycznej	–
Mar 18, 2019	KIO 382/19	Appellant	Szpital Uniwersytecki im. Karola Marcinkowskiego w Zielonej Górze sp. z o.o.	Discontinued
Feb 18, 2019	KIO 228/19	Appellant	Wielospecjalistyczny Szpital – Samodzielny Publiczny Zespół Opieki Zdrowotnej w Zgorzelcu	Authority accepted the complaints
Sep 25, 2018	KIO 1795/18	Appellant	Wojskowy Instytut Medycyny Lotniczej w Warszawie	Dismissed

Trademarks

Polska Grupa Farmaceutyczna holds 14 active trademarks registered with the Polish Patent Office. 2 applications are pending. 5 marks have expired or were not registered. The first mark was filed in 1998.

Mark	Number	Classes	Status	Protected until
lekko	Z.587616	3, 5, 16	Protected	Jul 17, 2035
e-pgf(word)	Z.529366	3, 5, 9, 10, 16, 35, 38, 41, 42, 44	Protected	May 26, 2031
na zdrowie	Z.505759	9, 10, 16, 30, 35, 38, 40, 41, 42, 44	Protected	Oct 17, 2029
ZDROWY WYBÓR	Z.492083	3, 5, 9, 10, 16, 30, 35, 38, 40, 41, 42, 44	Protected	Oct 26, 2028
POLSKA GRUPA FARMACEUTYCZNA	Z.204663	35, 36	Protected	Jul 12, 2029

Mark	Protected until
lekko	Jul 17, 2035
e-pgf(word)	May 26, 2031
na zdrowie	Oct 17, 2029
ZDROWY WYBÓR	Oct 26, 2028
POLSKA GRUPA FARMACEUTYCZNA	Jul 12, 2029

Regulatory authorisations

Authority	Type	Status
BDO	BDO register entry	Active

Authorized Representatives

Bartosz Kędzierski – Attorney-in-fact (joint)

Łukasz Grzelak – Management Board Member

Piotr Robert Jucha – President of the Management Board

Marek Lipka – Vice President of the Management Board

Manner of representation

For the validity of declarations of will made on behalf of the company, joint action of two members of the management board or of one member of the management board together with a commercial proxy is required. The commercial proxy makes declarations of will on behalf of the company jointly with one member of the management board.

Supervisory board

Mariola Belina Prażmowska – Supervisory Board Member

Jacek Dauenhauer – Supervisory Board Member

Ignacy Przystalski – Supervisory Board Member

Jacek Szwajcowski – Supervisory Board Member

Zbigniew Molenda – Supervisory Board Member

Ownership

Owner
Pelion S.A.

Beneficial owners

Person	Rights

Subsidiaries

Name	Share value	Stake
Polska Grupa Farmaceutycznasp. z o.o.	101,836.84 USD	60.9539%
PRZY Tobie - Program Wsparcia Biznesowego Apteksp. z o.o.	3,133,441.38 USD	100%
Pure Medicsp. z o.o.	405,186.39 USD	100%

Competitors

Name	Revenue	Website
Urticasp. z o.o.	$1,277,144,231.12	urtica.pl
Bayersp. z o.o.	$624,313,880.67	talent.bayer.com
Polski TytońS.A.	$620,174,679.16	polskityton.pl
Przedsiębiorstwo Dystrybucji Farmaceutycznej Slawexsp. z o.o.	$600,815,720.02	slawex.com.pl
Brenntag Polskasp. z o.o.	$548,791,874.18	brenntag.pl
Polskie Supermarketysp. z o.o.	$500,422,693.92	polomarket.pl
HurtapS.A.	$480,276,955.20	hurtap.com.pl
Centrala Farmaceutyczna CefarmS.A.	$457,052,669.59	cefarm.com.pl
Sanofisp. z o.o.	$384,123,246.36	sanofi.com
USP Zdrowiesp. z o.o.	$377,149,656.94	uspzdrowie.pl

Change history

Date	Event
2024-09-04	Share capital change (280,000,000.00 PLN → 290,000,000.00 PLN)
2021-05-28	Share capital change (372,000,000.00 PLN → 280,000,000.00 PLN)
2015-02-27	PKD change (Removed: 10.86.Z, 10.89.Z, 20.41.Z, 20.42.Z, 21.10.Z, 21.20.Z, 32.50.Z, 32.99.Z, 45.11.Z, 45.19.Z, 46.18.Z, 46.36.Z, 46.37.Z, 46.65.Z, 46.66.Z, 46.76.Z, 47.41.Z, 47.42.Z, 47.73.Z, 47.74.Z, 47.75.Z, 52.21.Z, 52.24.C, 52.29.C, 62.01.Z, 62.02.Z, 62.03.Z, 62.09.Z, 63.99.Z, 64.91.Z, 64.92.Z, 64.99.Z, 66.19.Z, 68.20.Z, 69.20.Z, 77.11.Z, 77.12.Z, 77.39.Z, 82.99.Z, 85.59.B, 96.09.Z)
2013-08-01	Entered in the register

FAQ

Last updated: 2026-10-07